Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This trial will compare the efficacy of irinotecan/cisplatin and pemetrexed/cisplatin in the
second-line treatment of patients with stage IIIB/IV NSCLC